Trial Profile
A DB, Randomized, Placebo-controlled Study of the Tolerability, Efficacy, Safety, and Dose Range of Intramyocardial CLBS14 for Reduction of Angina Episodes in Patients With Refractory Chronic Myocardial Ischemia (ACT34-CMI)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs CLBS-14 (Primary) ; CLBS-14 (Primary)
- Indications Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms ACT34-CMI
- Sponsors Caladrius Biosciences
- 06 Mar 2018 According to a Caladrius Biosciences media release, Douglas W. Losordo, MD, FACC, FAHA, Senior Vice President, Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius is the principal investigator of the study
- 05 Dec 2014 New trial record